- Home
- NNOX vs TVRD Comparison
NNOX vs TVRD Comparison
Compare NNOX & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NNOX
- TVRD
- Stock Information
- Founded
- NNOX 2011
- TVRD 2017
- Country
- NNOX Israel
- TVRD United States
- Employees
- NNOX N/A
- TVRD N/A
- Industry
- NNOX Medical Electronics
- TVRD Biotechnology: Pharmaceutical Preparations
- Sector
- NNOX Health Care
- TVRD Health Care
- Exchange
- NNOX Nasdaq
- TVRD Nasdaq
- Market Cap
- NNOX 253.8M
- TVRD 246.5M
- IPO Year
- NNOX 2020
- TVRD N/A
- Fundamental
- Price
- NNOX $4.33
- TVRD $39.91
- Analyst Decision
- NNOX Strong Buy
- TVRD Strong Buy
- Analyst Count
- NNOX 2
- TVRD 5
- Target Price
- NNOX $8.50
- TVRD $59.20
- AVG Volume (30 Days)
- NNOX 1.3M
- TVRD 68.2K
- Earning Date
- NNOX 11-20-2025
- TVRD 11-21-2025
- Dividend Yield
- NNOX N/A
- TVRD N/A
- EPS Growth
- NNOX N/A
- TVRD N/A
- EPS
- NNOX N/A
- TVRD N/A
- Revenue
- NNOX $11,886,000.00
- TVRD N/A
- Revenue This Year
- NNOX $20.50
- TVRD N/A
- Revenue Next Year
- NNOX $64.10
- TVRD N/A
- P/E Ratio
- NNOX N/A
- TVRD N/A
- Revenue Growth
- NNOX 17.36
- TVRD N/A
- 52 Week Low
- NNOX $3.60
- TVRD $8.13
- 52 Week High
- NNOX $11.00
- TVRD $42.10
- Technical
- Relative Strength Index (RSI)
- NNOX 50.50
- TVRD 68.51
- Support Level
- NNOX $3.60
- TVRD $39.44
- Resistance Level
- NNOX $4.15
- TVRD $42.10
- Average True Range (ATR)
- NNOX 0.17
- TVRD 2.65
- MACD
- NNOX 0.05
- TVRD 0.02
- Stochastic Oscillator
- NNOX 66.67
- TVRD 75.13
About NNOX NANO-X IMAGING LTD
Nano X Imaging Ltd is engaged in the business of manufacturing medical imaging systems. It offers a Nanox System which is a combination of hardware and software. It develops a prototype of the Nanox.ARC, a medical imaging system incorporating its novel digital X-ray source; and Nanox.CLOUD, a companion cloud-based software that will allow for the delivery of medical screening as a service. It has three business segments: Nanox.ARC division, the radiology services division and the AI solutions division. Key revenue is generated from Radiology Services.
About TVRD Tvardi Therapeutics Inc. Common Stock
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.